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Summary Following the positioning of a bare metal stent (BMS) implant, a yellow plaque is
healed with a reduction of the color grade and thrombogenicity, i.e. vulnerability by angioscopy
in the chronic phase (‘‘plaque sealing’’ of BMS; the ‘‘whitening effect’’ of BMS). However, we
have reported that thrombus and yellow plaque increases at the drug-eluting stent (DES) site.
A 71-year-old man underwent percutaneous coronary intervention using two DESs for a severe
stenotic lesion in his right coronary artery. Follow-up coronary angiography (CAG) showed in-
stent restenosis (ISR) at the stent-overlap site. We performed traditional balloon angioplasty,
but follow-up CAG showed ISR again at the same position as the ﬁrst restenosis. In angioscopic
ﬁndings, the normal vessel wall was white, but the site of DES implantation was yellow and
a yellow, soft, swelling neointimal proliferation-like vulnerable plaque was observed at the
restenotic site. In expectation of the ‘‘whitening effect’’ of BMS, we implanted a new BMS. As
anticipated, follow-up CAG showed no restenosis. Moreover, the angioscopic ﬁndings indicated
a clean, white, neointimal proliferation-like stable plaque at the BMS implant site in the yellow
vulnerable area of DES. The ‘‘BMS in DES’’ therapy should be considered one of the strategies
for ISR of DES.
© 2009 Published by Elsevier Ire
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ntroduction
ince the introduction of drug-eluting stents (DES), the prob-
em of restenosis of percutaneous coronary intervention
PCI) has been partially resolved. However, compared to
are metal stents (BMS), the risk of very late stent throm-
osis appears to be marginally higher and restenosis of DES
an occur. The deployment of DES to treat BMS restenosis has
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Figure 1 Coronary angiography. (A—D) On February 15, 2005, two SESs (3.0mm× 23mm and 3.5mm× 18mm) were successfully
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tmplanted at the stenotic lesion in the right coronary artery. (E—G
erformed plain old balloon angioplasty for the ﬁrst restenotic
e used a new BMS for the restenotic lesion. The arrows indica
ecome routine practice, but the strategy for DES restenosis
as not been established.
ase report
iagnostic angiography was conducted on a 71-year-old
ale complaining of chest pain and it revealed a signiﬁ-
ant stenotic lesion in the right coronary artery. Elective
CI of the lesion was performed, using two DES on Febru-
ry 15, 2005. A CypherTM stent (Cordis, Miami Lakes, FL,
SA) (3.0mm× 23mm; 16 atm) was initially implanted in
he distal position of the stenotic lesion and a CypherTM
tent (3.5mm× 18mm; 18 atm) was next implanted with
artial overlapping (Fig. 1A—D). He had some coronary
isk factors including diabetes mellitus, hypertension, and
ypercholesterolemia. Antihypertensives, statin, and insulin
ere administered after his admission. His blood pressure
as well controlled and his total cholesterol and low-
ensity lipoprotein cholesterol levels were 146—183mg/dl
nd 60—116mg/dl, respectively. Plasma glucose level was
19—159mg/dl and hemoglobin A1C was 6.1—6.6%. After
ne year, follow-up angiography revealed an initial resteno-
is at the stent overlapping position. Plain old balloon
ngioplasty was performed with a high-pressure balloon
ApolloHPTM; Avantec Vascular Corp., Sunnyvale, CA, USA)
3.25mm× 15mm; 20 atm) on March 2, 2006 (Fig. 1E—G).
fter 3 months, follow-up angiography revealed a second
estenosis at the same position. By angioscopy, the vessel
all was almost white, but the site of DES implantation was
B
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oer one year, he exhibited the ﬁrst restenosis and we successfully
n. (H—J) After 3 months, he exhibited a second restenosis and
e stenotic lesions.
ellow. Moreover, the second restenotic lesion exhibited a
ellow, soft, swelling neointimal proliferation-like vulnera-
le plaque. In anticipation of a ‘‘whitening effect’’ of BMS,
e implanted a new BMS (VisionTM; Abbot Vascular, Santa
lara, CA, USA) (3.5mm× 12mm; 20 atm) on July 25, 2006
Figs. 1H—J and 2). We performed follow-up angiography
nd angioscopy on January 23, 2007. Based upon angiogra-
hy, we were not able to ﬁnd a third restenosis. Angioscopic
ndings showed a white, clean neointimal proliferation-like
table plaque at the BMS implanted site in the yellow vul-
erable area of DES (Fig. 3). The patient has not exhibited
ny further restenosis until now.
iscussion
ngioscopy of the coronary artery can be used to identify
orphologic changes, especially plaque and thrombus for-
ation. For plaque formation, the more yellow the color,
he more vulnerable the disposition. In other words, dark
ellow plaques appear to have a lipid rich core with a thin
brous cap, i.e. suggesting vulnerability, whereas a white
laque is stable. With the introduction of DES, the problem
f restenosis after percutaneous stent implantation was par-
ially resolved. The deployment of DES to treat the ISR of
MS has become routine practice, while a strategy for the
SR of DES has yet to be established. Because the excessive
roliferation of neointima almost causes the ISR of BMS, DES
mplantation is an ideal strategy for it. The mechanism of ISR
f DES seems to be various, unknown and different from BMS.
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aFigure 2 Angioscopic ﬁndings at PCI for the second resten
(CypherTM) (a and c). The de novo lesion was white and DES
interpretation of the references to color in this ﬁgure legend, t
BMSs not only compress and cover yellow vulnerable plaques
with a protruding thrombus and intimal ﬂap, but also help
to seal the unstable plaque through neointimal prolifera-
tion [1]. BMS appear to exhibit a plaque-sealing effect and
we call this phenomenon the ‘‘whitening effect’’ of BMS.
DES reduces neointimal formation [2,3], but the existence
of stent surface thrombus and yellow plaque grade at the
stented site can worsen after SES implantation [4—7]. In our
case, angioscopic ﬁndings revealed yellow vessel wall only
at the DES site and especially a dark yellow swelling neoin-
tima or vulnerable plaque at the restenosis site. Because
we could not observe the culprit lesion by angioscopy at
the ﬁrst PCI, the lesion might have been yellow from the
beginning and remained with the same yellow color at the
i
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Figure 3 Angiographic and angioscopic ﬁndings at the last CAG. An
(VisionTM) (b) has changed from yellow to white intima in the yellow
stent; BMS, bare metal stent. (a and c) The positions of CypherTM; (b
to color in this ﬁgure legend, the reader is referred to the web versBMS (b) was implanted onto the yellow neointima over DES
yellow. DES, drug-eluting stent; BMS, bare metal stent. (For
ader is referred to the web version of the article.)
nd PCI. But, the vessel wall was white except at the yel-
ow site of DES implantation and we speculate that DES
akes a lipid pool and yellow thrombus such as angioscopic
ulnerable plaque. In addition, the restenosis site had a
ellow, soft, swelling neointimal proliferation-like vulner-
ble plaque and the stent was not visible by angioscopy.
his yellow swelling neointima of ISR was different from the
riginal culprit plaque. In anticipation of the ‘‘whitening
ffect’’ of BMS, we implanted a new BMS. As anticipated,
ngiogram demonstrated no restenosis and angioscopic ﬁnd-
ngs revealed a clean, white, neointimal proliferation-like
table plaque at the BMS implanted site. BMS can help to
eal the unstable plaque through stable neointimal prolif-
ration, but DES makes angioscopic vulnerable vessel wall
giography showed no restenosis. By angioscopy, the site of BMS
vulnerable area of DES (CypherTM) (a and c). DES, drug-eluting
) the position of VisionTM. (For interpretation of the references
ion of the article.)
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uch as yellow plaque and thrombus at the stented site.
he restenosis site of a yellow swelling neointima in DES
ight be unstable plaque such as vulnerable plaque or yel-
ow thrombus. Implantation of BMS seemed to have changed
yellow or vulnerable plaque into a white or stable plaque.
he ‘‘BMS in DES’’ therapy should be considered as one of
he strategies for ISR of DES.
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